Outcomes from elective colorectal cancer surgery during the SARS-CoV-2 pandemic

This study aimed to describe the change in surgical practice and the impact of SARS-CoV-2 on mortality after surgical resection of colorectal cancer during the initial phases of the SARS-CoV-2 pandemic

Onset of clinical immunity to \u3ci\u3ePlasmodium falciparum\u3c/i\u3e among Javanese migrants to Indonesian Papua

Onset of clinical immunity to Plasmodium falciparum occurred among Javanese migrants to Indonesian Papua. Surveillance of the 243 migrants investigated began on the day of their arrival in Indonesian Papua and continued for 33 months. Asexual parasitaemia without fever constituted objective evidence of clinical immunity. Compared with .rst infection, the odds ratio (OR) for not having fever at the fourth infection within 24 months was 3.2 [95% con.dence interval (CI)=1.03–10.2; P=0.02]. The corresponding OR with fewer infections within 24 months was not distinguishable from 1.0. The level of the fourth parasitaemia within 24 months (N=58) was classified as ‘high’ or ‘low’ in relation to the median count at first infection (840 parasites/ml; N=187). Fourth parasitaemias that were low —but not those that were high (OR=1.8; CI=0.6–5.4; P=0.35)— were associated with dramatic protection from fever (OR=31; CI=3.5–1348; P=0.0001). Among the adult subjects, the risk of fever with low parasitaemia was signi.cantly higher at the .rst infection than at the fourth (OR=12.6; CI=1.7–530; P=0.005), indicating the development of clinical immunity. A similar but less marked pattern appeared among the children investigated (OR=6.5; CI=0.8–285; P=0.06)

VERY HIGH RISK OF THERAPEUTIC FAILURE WITH CHLOROQUINE FOR UNCOMPLICATED \u3ci\u3ePLASMODIUM FALCIPARUM\u3c/i\u3e AND \u3ci\u3eP. VIVAX\u3c/i\u3e MALARIA IN INDONESIAN PAPUA

Chloroquine remains the first-line therapy for uncomplicated malaria in Indonesia. Among a series of trials of chloroquine for malaria on this archipelago conducted since 1990, we now report the highest risk of therapeutic failure yet observed. A clinical trial of standard chloroquine therapy for uncomplicated malaria at Arso PIR V in northeastern Indonesian Papua was conducted during 1995. We enrolled 104 non-immune subjects infected with Plasmodium falciparum (n=55), P. vivax (n=29), or P. falciparum plus P. vivax (n=20) and administered supervised standard chloroquine therapy (10 + 10 + 5 mg/kg at 24-hour intervals). The 28-day cumulative incidence of therapeutic failure was 95% for P. falciparum, 84% for P. vivax, and 100% for mixed infections. Only one subject each for P. falciparum and P. vivax remained free of parasites at day 28. All recurrent parasitemias occurred with whole blood levels of chloroquine plus desethylchloroquine exceeding 100 ng/ml. These findings document almost complete failure of chloroquine against P. falciparum or P. vivax near the northeastern coast of Indonesian Papua

Pneumonia in Military Trainees: A Comparison Study Based on Adenovirus Serotype 14 Infection

Background. Adenovirus serotype 14 (Ad-14) recently emerged as a respiratory pathogen in the United States, with studies suggesting higher morbidity and mortality. This study was conducted to determine whether Ad-14 is associated with clinical outcomes in otherwise healthy patients with pneumonia